MRD DLBCL Working Group

Co-Chairs

Duane Hassane, PhD

Senior Director, Head of Translational Omics, Hematology R&D

AstraZeneca

Allison Jacob

Vice President, Medical Affairs

Adaptive Biotechnologies

Current Projects

  • Lexicon:

    • Review the existing MRD lexicon to identify overlap and gaps relevant to a hematologic MRD lexicon.

  • MRD Assay Standardization & Reporting:

    • A white paper or peer review publication that discusses reporting standards, LOD95 guidance, variant quality, cross-platform comparison

  • Surrogacy Validation:

    • A consensus document that identifies data sources, qualification criteria, analytical goals, futility approach, and milestones for establishing MRD as a surrogate endpoint

Participating Organizations

Association for Molecular Pathology (AMP), AstraZeneca, Bristol Myers Squibb (BMS), Exact Sciences, Foresight Diagnostics (Natera), Genentech / Roche, J&J, LGC Group, Lilly, Natera, Novartis, nRichDx, PreAnalytiX, Roche, Thermofisher, University of Arkansas for Medical Sciences, Ultima Genomics, University of Ghent

Past Deliverables

Not applicable at this time.

Meetings

This working group meets on zoom every other Tuesday from 12:00 - 1:00 PM EST.

Special workshops and sessions:

Not applicable at this time.